Effect of glibenclamide on insulin release at moderate and high blood glucose levels in normal man

European Journal of Clinical Investigation

Volumn 27, Issue 8, 1997, Pages 685-689

  Ligtenberg, J J M ^a   Venker, C E ^a   Sluiter, W J ^a   Reitsma, W D ^a   Van Haeften, T W ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Glibenclamide; Hyperglycaemic clamp; Insulin secretion; Sulphonylurea derivatives

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; INSULIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030765964     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1710716.x     Document Type: Article

References (25)

1. Henquin JC. D-Glucose inhibits potassium efflux from pancreatic island cells. Nature 1978;271:271-3.
2. Ward WK, Bolgiano DC, McKnight B et al. Diminished B-cell secretory capacity in patients with NIDDM. J Clin Invest 1984;74:1318-28.
3. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984;312:446-8.
4. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-54.
5. Groop LC, Melander A, Groop P et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987;36:1320-8.
6. Van Haeften TW, Boonstra E, Veneman TF et al. Dose-response characteristics for glucose-stimulated insulin release in man and the assessment of influence of glucose on arginine stimulated insulin release. Metabolism 1990;39:1292-9.
7. Liu D, Moberg E, Kollind M et al. Arterial, arterialized venous, venous and capillary blood glucose measurements in normal man during hyperinsulinaemic euglycemia and hypoglycemia. Diabetologia 1992;35:287-90.
8. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
9. Tillil H, Shapiro ET, Rubenstein AH et al. Reduction of insulin clearance during hyperglycemic clamp. Dose-response study in normal humans. Diabetes 1988;37:1351-7.
10. Polonsky KS, Given BD, Hirsch L et al. Quantitative study of insulin secretion and clearance in normal and obese subjects J Clin Invest 1988;81:435-41.
11. Mitrakou A, Vuorinen-Markkola H, Raptis G et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemic clamp. J Clin Endocrinol Metab 1992;75:379-82.
12. Balant L, Zahnd GR, Weber F et al. Behaviour of glibenclamide on repeated administration to diabetic patients. Eur J Clin Pharmacol 1977;11:19-25.
13. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321:1231-45.
14. Wolffenbuttel BHR, Van Haeften TW. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Drugs 1995;50:263-88.
15. Boyd AE. The role of ion channels in insulin secretion. J Cell Biochem 1992;48:235-41.
16. Ligtenberg JJM, Van Haeften TW, Links TP et al. Clinical relevance of ATP sensitive potassium channels. Neth J Med 1995;47:241-51.
17. Aguilar-Bryan L, Nichols CG, Wechsler SW et al. Cloning of the B cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-6.
18. Pulido N, Casla A, Suarez A et al. Sulphonylurea stimulates glucose uptake in rats through an ATP-sensitive K+ channel dependent mechanism. Diabetologia 1996;39:22-7.
19. Simonson DC, Ferrannini E, Bevilacqua S et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 1984;33:838-45.
20. Kolterman OG, Gray RS, Shapiro JA et al. The acute and chronic effects of sulfonylurea therapy in type 2 diabetic subjects. Diabetes 1984;33:346-54.
21. Widstrom A, Cerasi E. On the action of tolbutamide in normal man. Modulation of glucose-induced insulin release by tolbutamide. Acta Endocrinol 1973;72:519-31.
22. Van Haeften TW, Veneman TF, Gerich JE et al. Influence of gliclazide on glucose-stimulated insulin release in man. Metabolism 1991;40:751-5.
23. Hosker JP, Rudenski AS, Burnett MA et al. Similar reductions of first and second phase β-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 1989;38:767-72.
24. Groop LC, Luzi L, DeFronzo RA et al. Hyperglycemia and absorption of sulfonylurea drugs. Lancet 1989;ii:129-30.
25. Groop LC, Harno K. Diurnal pattern of plasma insulin and blood glucose during glibenclamide and glipizide therapy in elderly diabetics. Acta Endocrinol 1980;239(Suppl):44-52.